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regarding isolated cases or small series exist (3). 
Six patients were enrolled in the study with a diag-
nosis of in situ skin cancer of genital area (Table 1). The 
case series included 5 men and 1 woman aged 39-75 
years (mean age 53 years). The patients were treated 
during a period from November 2010 to August 2012 
in our Dermatological Department. The clinical diag-
noses of all 6 patients were confirmed with histopa-
thology before starting the treatment: 4 patients were 
diagnosed with EQ of glans penis, 1 patient with BD of 
the perianal zone, and 1 patient with EMPD of inguinal 
crease (Figure 1). We decided to administer MAL-PDT 
therapy due to the site and/or the size of the lesions 
and the age of the patients.
None of the patients reported any known side-ef-
fects to the use of PDT. Informed consent was obtained 
before PDT treatment.
Patients underwent consecutive MAL-PDT ses-
sions: 3 hours after topical application of MAL emul-
sion (Metvix, GALDERMA, Italy), they underwent illu-
mination with red light (PDT 1200 L, Waldmann W) at 
a fluency of 75 J/cm² for 10 minutes. The light source 
used with MAL-PDT had a waveband of about 635 nm. 
During the exposure phase, control of the pain was 
achieved by infiltrating 1-2 cc lidocaine 2% infiltration 
in the area that resulted fluorescent using Wood’s light. 
Ventilation and cold water spray was administered to 
all patients to relieve the burning feeling. 
All the patients achieved a complete clinical and 
dermatological remission. In 2 of the cases with EQ of 
glans penis and in the case with BD and in the case of 
EMPD, 3 sessions of MAL-PDT (2 consecutive weekly 
Table 1. Description of the population
n Female/
Mmale
Age Localization Histopathology Topical methylaminolevulinate 
– photodynamic therapy sessions
1 M 39 Glans penis EQ 6 sessions
2 M 61 Glans penis EQ 6 sessions
3 M 30 Glans penis EQ 3 sessions
4 M 44 Glans penis EQ 3 sessions
5 F 68 Perianal zone/nipple BD 3 sessions
6 M 75 Inguinal crease EMPD 3 sessions
Intraepithelial cutaneous squamous cell carcino-
ma (SCCIS) of genital area can be referred to as Bowen’s 
Disease (BD) or erythoplasia of Queyrat (EQ) according 
to localization and clinical presentation.
BD is an intraepithelial squamous cell carcinoma 
with the potential to become an invasive carcinoma. 
It can be localized anywhere on the skin and the geni-
tal area, in particular over the vulva, perineum, or the 
inguinal crease and glans penis. Clinically it usually ap-
pears as an erythematous or hyperpigmented, scaling, 
sharply demarcated plaque.
SCCIS localized on the mucosal or transitional sur-
face of glans penis, also referred to as EQ, is regarded as 
a premalignancy in the squamous epithelial cell layer 
of the skin and may develop into invasive carcinoma. 
The risk of invasive carcinoma is estimated to be high-
er for EQ, at 10%, in comparison to SCCIS of the skin, 
which might be linked to mucosal involvement. Clini-
cally it usually appears as an inflammatory plaque (1).
EMPD is an extremely rare form of intraepithelial 
adenocarcinoma that may have an underlying tumor 
component (only a few hundred reports are available 
in the reviewed literature). It affects apocrine gland-
bearing areas and most commonly occurs on the peri-
anal zone and nipple (2).
The first choice treatment for these types of skin 
cancers is surgical excision, which is often difficult 
due to the cancer location and the extension of the 
lesion and might require large margins with recon-
structive surgery. The use of non-invasive alternative 
procedures, such as photodynamic therapy, has been 
considered for treatment, although only a few reports 
149ACTA DERMATOVENEROLOGICA CROATICA
Letter to the editor Acta Dermatovenerol Croat
2015;23(2):148-149
sessions and a third session after 2 weeks) were suffi-
cient. The other 2 cases with EQ of glans penis required 
6 sessions of MAL-PDT (2 consecutive weekly sessions 
and a third session after 2 week, repeated twice). The 
follow-up schedule was checked one month after the 
end of treatment, and then every six months. The clini-
cal and dermatoscopical follow up demonstrated no 
sign of recurrence over an average post-treatment 
period of 9 months (observational FU range 9-24 
months).
The case series that we propose is heterogeneous 
but is interesting because in genital area is always dif-
ficult to propose a destructive surgery and more con-
servative options have to be taken into consideration. 
Skin preserving and cosmetic result has to be consid-
ered in therapeutic choice. 
PDT can be considered a valid alternative for cancer 
control, organ preservation, cosmetics, shorter healing 
times and functional results (4). According to literature 
evidence, surgery remains the standard therapy for 
those cancers, when it is practicable though the rates of 
recurrence with PDT are comparable to surgery (5-6).
The results of our study, though based on a limited 
sample of patients, are promising; we obtained com-
plete remission in 100% of the cases but it is essential a 
long-term follow-up and a final evaluation of the effec-
tiveness of the therapy is for the moment premature. 
Our data available on relapse rates at 9 months follow-
up (FU) show encouraging results.
A surgical approach is still possible as the second 
stage intervention, if considered necessary.
In the case of patients with multiple and extended 
lesions, an improvement in number and size reduction 
may also be considered a good result for the aesthetic 
outcome since surgery can then be less extensive. 
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Figure 1. Bowen disease: Before (a) photodynamic 
therapy (PDT) sessions and after (b) the third session.
a)
b)
